Asian share markets are mixed today, following a drop in US stocks on Friday with investors locking in profits.

Equity markets are currently trading in green following a muted opening, ahead of critical reading on US inflation.

The Nikkei is up 0.7% while the Shanghai Composite added 1.1%. Hang Seng is trading higher by 1.4%.

Wall Street indices ended lower on Friday in US stock markets after a solid jobs report ate into hopes for a pause in the Federal Reserve's aggressive policy-tightening, needed to curb the decades-high inflation.

The Dow Jones fell 1.1% while the Nasdaq plunged 2.5%.

Back home, Indian share markets are trading on a negative note.

Benchmark indices opened on a negative note tracking the trend on SGX Nifty live chart and amid unsupportive global cues.

The Reserve Bank of India will begin its three-day monetary policy committee (MPC) meeting later today.

FII & DII activity is widely tracked. FII outflows from equities have reached Rs 1.69 lakh crore so far in 2022.

The BSE Sensex is trading down by 231 points. Meanwhile, the NSE Nifty is trading lower by 67 points.

NTPC and Axis Bank are among the top gainers today. Bajaj Finserv and Tech Mahindra, on the other hand, are among the top losers today.

The BSE Mid Cap index is down 0.7%. The BSE Small Cap index is trading lower by 0.6%.

Sectoral indices are trading mixed with stocks in the IT sector and realty sector witnessing most of the selling.

Energy stocks, on the other hand, are trading in green.

IT stocks are trading on a cautious note today. Last Friday, IT stocks rallied tracking a rally in US markets, among other reasons.

Shares of DHP India and Elecon Engineering hit their 52-week highs today.

Continuing the downtrend, LIC's share price fell further and hit a new low of Rs 796 today.

With the stock market recovering, you should have a clear strategy by your side to navigate the markets.

The rupee is trading at 77.66 against the US$.

Gold prices are trading up by 0.3% at Rs 51,121 per 10 grams. Meanwhile, silver prices zoomed 1.3% to Rs 62,475 per kg.

Gold is steady after dropping about 1% in the previous session, following a robust US jobs report that signaled more interest rate increases this year.

Crude oil prices rose more than US$2 in early trade today after Saudi Arabia raised prices sharply for its crude sales in July.

In news from the automobile sector, TVS Motor is among the top buzzing stocks today.

The company's 2021-22 annual report suggests it has robust plans to scale up its play in the electric vehicle segment.

TVS Motor Company aims to build a sustained dominant play in the electric vehicle (EV) segment by leveraging various government initiatives like the production-linked incentive (PLI) schemes, among others.

Here's an excerpt from the report:

The industry is slated to grow rapidly and the company has robust plans for this segment.

In addition, with the strategic association with BMW, the company will be exploring the joint design and development of urban EV options for the global markets.

In the year gone by, TVS sold more than 10,000 EVs.

During the year ended March 2022, the company's overall two- and three-wheeler sales, including international business, grew by 8%.

TVS expects to outperform the industry in terms of sales growth on the back of new product launches and economic activity once again gathering pace.

Speaking of EVs, have a look at the chart below which shows the massive opportunity for the two-wheeler EVs.

Moving on to news from the pharma sector, Sun Pharma is looking to increase its field force in the domestic market by 10% in the current fiscal.

The drug major is doing this in order to drive twin objectives of brand focus and geographical expansion.

Sun Pharma currently employs around 11,000 medical representatives (MRs) and related staff in the country.

The company's CEO of India business Kirti Ganorkar said that the field force expansion done in fiscal 2021 has met with good success and considering the current market conditions, the company will be undertaking a further expansion.

The company's India formulations sales for the full-year fiscal 2022 stood at Rs 127.6 bn recording a 23% growth over fiscal 2021.

Sun Pharma caters to more than 100 countries across the globe.

For fiscal 2022, the company's revenues crossed the US$5 bn milestones while the adjusted net profit went past the US$1 bn mark.